From PGF2α-isopropyl ester to latanoprost: A review of the development of xalatan: The proctor lecture

Investigative Ophthalmology and Visual Science

Volumn 42, Issue 6, 2001, Pages 1134-1145

  Stjernschantz, J W ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; ESTER; ISOPROPYL ESTER; LATANOPROST; PROSTAGLANDIN; PROSTAGLANDIN F2 ALPHA; TIMOLOL; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; PROSTAGLANDIN F; PROSTAGLANDIN F2 ISOPROPYL ESTER;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GLAUCOMA; HISTORY OF MEDICINE; HUMAN; HYPERTRICHOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; AWARDS AND PRIZES; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; HEALTH CARE ORGANIZATION; INTRAOCULAR PRESSURE; MELANOSIS; OPHTHALMOLOGY; RESPIRATORY SYSTEM; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AWARDS AND PRIZES; DINOPROST; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MELANOSIS; MOLECULAR STRUCTURE; OPHTHALMOLOGY; PROSTAGLANDINS F, SYNTHETIC; RESPIRATORY SYSTEM; SOCIETIES, SCIENTIFIC;

EID: 0034744394     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. 2α
2. 2α-1-isopropyl ester
3. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals
4. 2α ester prodrugs and receptor selective prostaglandin analogs
5. 2α isopropyl ester versus iloprost phenacyl ester in rabbit and beagle eyes
6. 2α-1-isopropylester in the cynomolgus monkey
7. 2, and their esters in glaucomatous monkey eyes
8. 2α on cat and rhesus monkey eyes
9. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes
10. 2α on aqueous humor dynamics of rabbit, cat, and monkey
11. The putative and demonstrated miotic effects of prostaglandins in mammals
12. 2α-isopropylester eye drops: Effects in normal human eyes
13. 2α in the human eye
14. 2α on intraocular pressure in normotensive human subjects
15. 2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients
16. 2α-isopropylester eye drops: Effect on intraocular pressure in open angle glaucoma
17. 2α-isopropylester to timolol in patients with open angle glaucoma: A randomized, masked, placebo-controlled study
18. 2α-1-isopropyl ester to timolol in glaucoma patients
19. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment
20. 2α-induced ocular hypotension in monkeys
21. 2α increases uveoscleral outflow in the cynomolgus monkey
22. 2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow
23. Studies on characterisation of prostanoid receptors: A proposed classification
24. Prostanoids and their receptors
25. International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
26. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids
27. Species differences in the responses of the eye to irritation and trauma: A hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research
28. Autacoids and neuropeptides
29. Mediation of the ocular response to injury and irritation: Peptides versus prostaglandins
30. 1
31. Structure-activity correlations for prostanoid action
32. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes
33. 2α effects on intraocular pressure negatively correlate with FP-receptor stimulation
34. Phenyl substituted prostaglandin analogs for glaucoma treatment
35. Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents
36. 2α isopropyl ester: Potential antiglaucoma agents
37. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes
38. 1 and FP receptor agonists
39. Effects of latanoprost and related prostaglandin analogues
40. 2α analogue
41. 2α in human ciliary smooth muscle cells
42. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells
43. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells
44. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow
45. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro
46. Effects of prostaglandins on uveoscleral outflow
47. 2α treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathway
48. Effect of latanoprost on the extracellular matrix of the ciliary muscle: A study on cultured cells and tissue sections
49. 2α-induced ocular hyperemia
50. 2α-induced ocular surface hyperemia by sensory nerves in rabbits
51. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye
52. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys
53. 2α on the airway resistance of healthy and asthmatic men
54. 2 on airway conductance in healthy subjects and asthmatic patients
55. 2α
56. Prostaglandins and the lung
57. The lack of respiratory, effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma
58. Latanoprost and respiratory function in asthmatic patients: Randomized, double-masked, placebo-controlled crossover evaluation
59. 2α on bronchial smooth muscle in vitro
60. PhXA34, a new potent ocular hypotensive drug: A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers
61. 2α analogue: Effect on intraocular pressure in patients with ocular hypertension
62. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension
63. 2α-isopropyl ester analogues for glaucoma treatment
64. 2α analogue, after topical application in normal and ocular hypertensive human eyes
65. 2α analog, on aqueous humor dynamics in human eyes
66. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: A one-month study
67. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: Comparison of dose regimens
68. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol
69. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma
70. Dose-finding study with PhXA41 (latanoprost) in patients with elevated intraocular pressure
71. 2α analogue (PhXA41): An in-hospital, placebo-controlled study
72. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients: A randomized, double-masked comparison with timolol 0.5%
73. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure
74. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension
75. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol
76. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States
77. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
78. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study
79. Latanoprost, a prostaglandin analog, for glaucoma therapy: Efficacy and safety after 1 year of treatment in 198 patients
80. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol
81. Latanoprost: Two years' experience of its use in the United Kingdom
82. Latanoprost: Experience of 2-year treatment in Scandinavia
83. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
84. Iris-color change developed after topical isopropyl unoprostone treatment
85. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost
86. Latanoprost and hyperpigmentation of eyelashes
87. Anterior uveitis associated with latanoprost
88. Cystoid macular edema and anterior uveitis associated with latanoprost use: Experience and incidence in a retrospective review of 94 patients
89. Latanoprost and cystoid macular edema: Is there a causal relation?
90. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents
91. 2α analogue, and timolol in patients with elevated intraocular pressure
92. Additive ocular hypotensive effect of latanoprost and acetazolamide: A short-term study in patients with elevated intraocular pressure
93. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability
94. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: A study on patients with elevated intraocular pressure
95. Significance and time-course of prostaglandin-induced increase in iridial pigmentation in primates and man
96. Prostaglandin-induced iridial pigmentation in primates
97. α-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro
98. 2α and latanoprost on cultured human iridal melanocytes
99. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines
100. Immunohistochemical evaluation of the iris with proliferation markers after treatment with latanoprost
101. The morphology if irides treated with latanoprost: A review of current studies
102. Morphological evaluation of the iris after treatment with latanoprost
103. Histopathological findings in iris specimens from patients with glaucoma treated with latanoprost
104. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys
105. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes
106. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue
107. 2α receptor messenger RNA and protein in the cynomolgus monkey eye
108. Genetic variation in the coding regions of the FP prostanoid receptor in patients exhibiting increased pigmentation of the iris during latanoprost treatment
109. 2 receptors
110. Protein kinase C-β activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain
111. Effects of prostaglandins upon hair growth in mice
112. Transdermal viprostol in the treatment of male pattern baldness
113. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin
114. Prostaglandins, other eicosanoids, and their derivatives as potential antiglaucoma agents